Compare Intuit Inc. (INTU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Neurocrine Biosciences Inc — how do they compare? Intuit Inc. trades at $329.49 (market cap $92.03B), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Intuit Inc. is far larger — about 5.6× Neurocrine Biosciences Inc's market cap, and Intuit Inc. pays a 1.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| INTU | NBIX | |
|---|---|---|
Market Cap | $92.03B | $16.46B |
Sector | Technology | Health |
52-Week High | $717.21 | $185.50 |
52-Week Low | $255.07 | $123.10 |
Enterprise Value | $90.49B | $16.48B |
Dividend Yield | 1.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.
The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
